INFLIXIMAB MODULATES MUCOSAL CYTOKINE PROFILE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

被引：0
|
作者：
Caprioli, F. [1 ]
Bose, F. [2 ]
Raeli, L. [2 ]
Vigano, C. [3 ]
Basilisco, G. [1 ]
Conte, D. [3 ]
Abrignani, S. [2 ]
Reali, E. [2 ]
机构：
[1] Fdn IRCCS Osped Maggiore Policlin Mangiagalli & R, Gastroenterol Unit 2, Milan, Italy
[2] INGM, Milan, Italy
[3] Univ Milan, Dept Med Sci, Milan, Italy
来源：
DIGESTIVE AND LIVER DISEASE | 2010年 / 42卷
关键词：
D O I：
10.1016/S1590-8658(10)60175-2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P.62
引用
收藏
页码：S125 / S125
页数：1
相关论文
共 50 条
  • [21] SERUM INFLIXIMAB LEVELS,ANTIBODIES TO INFLIXIMAB AND ALBUMIN CONCENTRATIONS DURING INFLIXIMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
    Malickova, K.
    Janatkova, I.
    Duricova, D.
    Bortlik, M.
    Lukas, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (01) : 213 - 213
  • [22] Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
    Ungar, Bella
    Levy, Idan
    Yavne, Yarden
    Yavzori, Miri
    Picard, Orit
    Fudim, Ella
    Loebstein, Ronen
    Chowers, Yehuda
    Eliakim, Rami
    Kopylov, Uri
    Ben-Horin, Shomron
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (04) : 550 - +
  • [23] New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases
    Nemoz, Benjamin
    Ternant, David
    Bailly, Sebastien
    Gautier-Veyret, Elodie
    Jourdil, Jean-Francois
    Bonaz, Bruno
    Stanke-Labesque, Francoise
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (04) : 722 - 728
  • [24] Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases
    Papamichael, Konstantinos
    Clarke, William T.
    Vande Casteele, Niels
    Germansky, Katharine A.
    Feuerstein, Joseph D.
    Melmed, Gil Y.
    Siegel, Corey A.
    Irving, Peter M.
    Cheifetz, Adam S.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (04) : 839 - +
  • [25] The persistence of subcutaneous infliximab is equivalent to intravenous form in patients with inflammatory bowel diseases
    Bothorel, L.
    Laharie, D.
    Poullenot, F.
    Gohier, E.
    Chevrier, C.
    Berger, A.
    Zerbib, F.
    Riviere, P.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1490 - I1490
  • [26] ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases
    Jung, Eun Suk
    Choi, Ko-Woon
    Kim, Seung Won
    Huebenthal, Matthias
    Mucha, Soeren
    Park, Jihye
    Park, Zewon
    Ellinghaus, David
    Schreiber, Stefan
    Franke, Andre
    Oh, Woo Yong
    Cheon, Jae Hee
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (10) : 1727 - 1735
  • [27] Infliximab infusion time in patients with inflammatory bowel diseases: Is longer really safer?
    Belhassan, Mehdi
    Zeitoun, Jean-David
    Lefevre, Jeremie H.
    Charachon, Antoine
    Amiot, Aurelien
    Le Baleur, Yann
    Sobhani, Iradj
    Delchier, Jean-Charles
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2013, 37 (02) : 189 - 192
  • [28] Updates in mucosal immunology for inflammatory bowel diseases
    Abreu, Maria T.
    CURRENT OPINION IN GASTROENTEROLOGY, 2018, 34 (06) : 375 - 376
  • [29] Chronic inflammatory Bowel Diseases - Infliximab seems to be safe
    Weiss, Johannes
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2013, 51 (11):
  • [30] Infliximab in pediatric inflammatory bowel diseases: the Geneva experience
    Mueller, P.
    Rivier, A. Giroud
    Tempia-Schaeppi, M.
    Belli, D. C.
    SWISS MEDICAL WEEKLY, 2008, 138 : 41S - 41S
12345